Special Issue

Synthesis of Compounds with Cytotoxic Activity

Message from the Guest Editor

Cancer is one of the leading causes of mortality worldwide, and the limited success of currently used anticancer drugs is a driving force for the search of new compounds with anticancer potential. A great number of such compounds are being synthesized in laboratories all over the world. The main challenge is to find a relatively simple, efficient, and generally synthetic method which enables preparation of libraries of compounds containing one or more pharmacophoric groups (hybrid molecules) with hope for new, effective anticancer agents. In addition, great attention is given to the diastereo- and enantioselective synthesis of these compounds. This Special Issue is devoted to all aspects of synthetic methodologies which enable preparation of compounds with known or potential cytotoxic activity, including new synthetic protocols and improvement of the existing ones, as well as catalytic or multicomponent syntheses. Further, evaluation of the cytotoxicity of novel compounds, their structure–activity relationship, and molecular mechanisms of action is welcomed.

Guest Editor

Prof. Dr. Tomasz Janecki

Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, Łódz, Poland

Deadline for manuscript submissions

closed (20 May 2021)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/32159

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).